Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136316 | 0.76 | CYP1A2 (0.43) | KDM4EGAAPDPK1CYP3A4MAP2K4 | |
| SCHEMBL1947333 | 0.76 | PDPK1 (0.50) | KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL16097568 | 0.73 | KDM4E (0.31) | KDM4EGAAPDPK1CYP3A4IDO1 | |
| SCHEMBL2016070 | 0.73 | KDM4E (0.41) | KDM4EALDH1A1IDO1 | |
| SCHEMBL2301862 | 0.72 | CNR1 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL15330376 | 0.72 | — | — | |
| SCHEMBL10468778 | 0.72 | MAP2K1 (0.37) | — | |
| SCHEMBL8777058 | 0.71 | IDO1 (0.55) | KDM4EGAAPDPK1CYP3A4MAP2K4 | |
| SCHEMBL10468234 | 0.69 | NOS1 (0.35) | KDM4ECYP3A4ALDH1A1HPGDMAPK1 | |
| SCHEMBL16617122 | 0.68 | CNR1 (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728136-B2 | Such as 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one via coupling piperazine derivative with alkyl halide by heating in solvent free conditions | LUPIN LIMITED (IN) | 2010-06-01 | — | — | US | claimed |
| US-20070238877-A1 | Novel Method for the Preparation of Aryl Piperazinyl-Heterocyclic Compounds | LUPIN LIMITED (IN) | 2007-10-11 | — | — | US | claimed |
| WO-2006011157-A2 | METHODS FOR THE PREPARATION OF ARYL PIPERAZINYL-HETEROCYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2006-02-02 | — | — | WO | claimed |
| EP-0900088-B1 | INCLUSION COMPLEXES OF ARYL-HETEROCYCLIC SALTS | PFIZER (US) | 2004-01-14 | — | — | EP | claimed |
| US-20010031756-A1 | Inclusion complexes of aryl-heterocyclic salts | KIM YESOOK (US) | 2001-10-18 | — | — | US | claimed |
| US-6232304-B1 | ZIPRASIDONE OR SALT MIXED OR COMPLEXED WITH CYCLODEXTRIN; INCREASING DRUG SOLUBILITY AND STABILITY | PFIZER INC. | 2001-05-15 | — | — | US | claimed |
| US-6127372-A | FOR TREATMENT OR PREVENTION OF VIRAL DISEASES, ESPECIALLY AIDS OR HIV | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-10-03 | — | — | US | claimed |
| EP-0900088-A2 | INCLUSION COMPLEXES OF ARYL-HETEROCYCLIC SALTS | PFIZER INC. (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997041896-A2 | INCLUSION COMPLEXES OF ARYL-HETEROCYCLIC SALTS | PFIZER INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4399198-A2 | DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 | Taipei Medical University (TW) | 2024-07-17 | — | — | EP | disclosed |
| EP-3617194-B1 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023130012-A1 | COMPOUNDS FOR MUTANT KRAS PROTEIN DEGRADATION AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023035005-A2 | DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 | TAIPEI MEDICAL UNIVERSITY (TW) | 2023-03-09 | — | — | WO | disclosed |
| EP-0584903-A1 | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| US-5206366-A | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | KDM4E 1984/4885GAA 3374/4885PDPK1 1458/4885 |
| US-20070238877-A1 | Novel Method for the Preparation of Aryl Piperazinyl-Heterocyclic Compounds | AQP1, AQP3, AQP4 | KDM4E 3340/4885GAA 539/4885PDPK1 3499/4885 |
| US-20010031756-A1 | Inclusion complexes of aryl-heterocyclic salts | SBDS, SORD, TBCD | KDM4E 2741/4885GAA 600/4885PDPK1 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.